TY - JOUR
T1 - Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
AU - De Paola, F.
AU - Ridolfi, R.
AU - Riccobon, A.
AU - Flamini, E.
AU - Barzanti, F.
AU - Granato, A. M.
AU - Mordenti, G. L.
AU - Medri, L.
AU - Vitali, P.
AU - Amadori, D.
PY - 2003/1/27
Y1 - 2003/1/27
N2 - We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) ε chain, p56lck, Fas ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2 and high Bax expression. Notably, they also expressed FasL. After 41-48 days of IL-2 culture, TCR ε chain and p56lck expression of TIL rose to median values of approximately 80 and 30% positive cells, respectively (P
AB - We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) ε chain, p56lck, Fas ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2 and high Bax expression. Notably, they also expressed FasL. After 41-48 days of IL-2 culture, TCR ε chain and p56lck expression of TIL rose to median values of approximately 80 and 30% positive cells, respectively (P
KW - IL-2
KW - TIL
KW - Tumour immunosuppression
UR - http://www.scopus.com/inward/record.url?scp=0037468099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037468099&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6600679
DO - 10.1038/sj.bjc.6600679
M3 - Article
C2 - 12610520
AN - SCOPUS:0037468099
VL - 88
SP - 320
EP - 326
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -